



**Canadian
Blood
Services**

BLOOD
PLASMA
STEM CELLS
ORGANS
& TISSUES

1800 Alta Vista Drive
Ottawa ON
K1G 4J5
Canada

INFORMATION ONLY

Leukoreduced Whole Blood Clinical Studies: Second Update
Customer Letter # 2024-34

2024-11-20

Dear Colleagues:

Further to Customer Letter #2024-30, Canadian Blood Services has now developed a process to intake and assess requests from hospitals participating in clinical studies involving Leukoreduced Whole Blood (LrWB).

Eligibility criteria for studies that will permit access to LrWB have been established. Please refer to Attachment 1, "LrWB Eligibility Criteria". Hospitals that meet the eligibility criteria are invited to contact the regional Hospital Liaison Specialist to obtain the "LrWB Study Application Form". Canadian Blood Services will start accepting applications immediately. All customers will be contacted as to whether their application has been accepted or rejected. Access to LrWB is constrained by red cell component inventory levels and as such, acceptance does not guarantee that Leukoreduced Whole Blood will be available in all cases.

The date for Canadian Blood Services to start manufacturing of Leukoreduced Whole Blood for non-military clinical studies is January 20, 2025.

Canadian Blood Services has also removed the note that indicated "for military use only" attached to the [Circular of Information](#) for Whole Blood Leukocytes Reduced to reflect availability for civilian use.

Please share a copy of this customer letter with healthcare professionals at your hospital who might be interested in this information.

This customer letter can also be viewed at www.blood.ca in the "Hospital Services" section. If you have questions about this letter, or if you require it in an accessible format, please contact your local hospital liaison specialist.

Sincerely,

Dr. Tanya Petraszko
Senior Medical Director, Medical, Laboratory and Stem Cell Services